Aktuellt
SENASTE
With the 2.5 MEUR grant from the European Innovation Council (EIC) Accelerator Programme, Elicera is now fully financed to complete a clinical phase I/II to evaluate its CAR T-cell therapy ELC-301 for treatment of B-cell lymphoma. The grant was awarded in fierce competition (only 5% of applications are approved) and provides validation of Elicera’s science and research. Corresponding to a 1.3 SEK per share the grant also releases resources to other portfolio projects. Consequently, we now find support for a fair value of 13 (12) SEK per share in 12 to 24 months.
LÄS MER
